Determinants of Outcome of Compensated Hepatitis C Virus-Related Cirrhosis

table 1. Baseline Characteristics of Interferon-Treated Patients and Untreated Patients

	Treated Patients (n = 59)	Untreated Patients (n = 44)

Age at diagnosis (y)^*	55 ± 9	56 ± 14
Sex (M/F)	39/20	33/11
Transfusion (%)	63	55
IVDU (%)	8	18
Duration of HCV infection (yr)^*	16 ± 9	18 ± 10
Hepatomegaly (%)	51	49
Splenomegaly (%)	20	32
BMI^*	25 ± 4	25 ± 4
ALT (IU/L)^*	108 ± 65	96 ± 68
AST (IU/L)^*	83 ± 36	85 ± 64
GGT (IU/L)^*	88 ± 71	84 ± 52
Alkaline phosphatase (IU/L)^*	72 ± 28	70 ± 27
Prothrombin time (%)^*	82 ± 13	77 ± 16
Bilirubin (mg/dL)^*	0.93 ± 0.35	0.99 ± 0.53
Albumin (g/dL)^*	3.9 ± 0.5	3.9 ± 0.5
Child-Pugh score: A (%)	95	87
B (%)	5	13
Platelets (10⁹/L)^*	142 ± 48	124 ± 49
AFP (µg/L)^*	15 ± 27	25 ± 42
Anti-HBc + (%)	32	30
Genotype 1b (%)	48	48
Knodell score^*	10 ± 2.5	10 ± 2.2

^* Mean ± SD. In patients with known risk factors. Abbreviations: IVDU, iv drug use; BMI, body/mass index; AST, aspartate aminotransferase; GGT, gamma glutamyl transpeptidase; AFP, -fetoprotein; HBc, hepatitis B core.